Literature DB >> 2946915

"Selective" D-1 and D-2 receptor antagonists fail to differentially alter supersensitive locomotor behavior in the rat.

M Amalric, G F Koob, I Creese, N R Swerdlow.   

Abstract

The dopamine receptor antagonists SCH 23390 and spiperone show highly selective in vitro affinity for D-1 and D-2 dopamine receptor subtypes, respectively. We studied the effects of these selective antagonists on the supersensitive locomotor response to apomorphine in rats following 6- hydroxydopamine (6OHDA) lesions of the nucleus accumbens (N. Acc.). Both D-1 and D-2 receptor antagonists produced dose-dependent blockade of the supersensitive locomotor response at doses that did not depress baseline locomotor activity. The behavioral properties of these D-1 and D-2 receptor antagonists were further examined using a simple step-down motor task. Both antagonists produced catalepsy as evidenced by dose-dependent increases in step- down latency. These results indicate that drugs with distinct in vitro dopamine binding affinities cannot be distinguished on the basis of their ability to inhibit supersensitive locomotor activity or simple motor tasks in rats in vivo.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2946915     DOI: 10.1016/0024-3205(86)90322-x

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  3 in total

1.  Effects of selective D1 and D2 dopamine antagonists on the development of behavioral sensitization to apomorphine.

Authors:  B A Mattingly; J K Rowlett; J T Graff; B J Hatton
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

2.  Human dopamine receptor subtypes--in vitro binding analysis using 3H-SCH 23390 and 3H-raclopride.

Authors:  H Hall; L Farde; G Sedvall
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

3.  Chronic treatment with the D1 receptor antagonist, SCH 23390, and the D2 receptor antagonist, raclopride, in cebus monkeys withdrawn from previous haloperidol treatment. Extrapyramidal syndromes and dopaminergic supersensitivity.

Authors:  H Lublin; J Gerlach; L Peacock
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.